Arcutis Biotherapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Arcutis Biotherapeutics, Inc. filed a Form 8-K reporting results from its 2022 Annual Meeting of Stockholders held on June 1, 2022. Shares outstanding and entitled to vote as of the April 4, 2022 record date totaled 51,417,963.
Key Financial and Operating Metrics
This filing does not report revenue, profit, cash flow, margins, debt, liquidity, or other financial operating metrics. The filing concerns stockholder voting matters.
Voting Results and Material Changes
- Proposal 1: Bhaskar Chaudhuri, Ph.D., Howard G. Welgus, M.D., and Sue-Jean Lin were elected as Class II directors to serve until the 2025 annual meeting or until their successors are elected.
- Proposal 2: Stockholders ratified Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022, with 47,070,314 votes for, 48,136 against, and 14,428 abstentions.
- Proposal 3: Stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, with 41,014,256 votes for, 2,066,501 against, and 501,677 abstentions.
- Proposal 4: Stockholders approved, on a non-binding advisory basis, holding future advisory votes on named executive officer compensation every one year. The one-year option received 43,397,406 votes, compared with 3,570 for two years and 104,713 for three years.
The filing does not present a comparable prior-period vote or identify any material financial change.
Guidance, Outlook, Risks, and Unusual Items
No financial guidance, business outlook, risk update, contingency, or unusual financial item is provided. Broker non-votes totaled 3,550,444 for each proposal where applicable. No other matters were submitted for stockholder action.
Important Facts to Verify
- Confirm the elected directors’ terms and subsequent board composition.
- Verify Ernst & Young LLP’s appointment for the fiscal year ending December 31, 2022.
- Review the definitive proxy statement filed April 19, 2022 for proposal details and voting standards.
- Confirm the filing’s vote totals and the one-year frequency outcome for future say-on-pay votes.